Known safety concerns, contraindications, and risk factors.
The compounds discussed here are not approved as therapeutics in the United States, United Kingdom, or European Union. This protocol describes what the research literature reports about their mechanisms and use in other jurisdictions. It is not medical advice, not a prescription, and not a recommendation to self-administer any substance. If you choose to use any of these compounds, do so with qualified medical supervision, pharmaceutical-grade sourcing, and full awareness of the legal status in your country.
Active or recent (within 5 years) malignancy
Epitalon activates telomerase — a hallmark of ~90% of human cancers — providing a plausible mechanism for accelerating sub-clinical disease. CJC-1295 and Ipamorelin raise GH and IGF-1, which are mitogenic. Both mechanism classes should be avoided.
Pregnancy or breastfeeding
No safety data exists for fetal or neonatal exposure to any compound in this protocol. Broadly contraindicated across the entire peptide class.
Uncontrolled diabetes or severe insulin resistance
CJC-1295 and Ipamorelin elevate GH, which directly worsens insulin resistance. Expected to destabilise glycaemic control.
Severe or unstable cardiovascular disease
Vasodilatory and tachycardic responses to CJC-1295 and transient fluid shifts from GH elevation carry unacceptable risk in this population.
Competitive athletes under WADA jurisdiction
Ipamorelin and CJC-1295 are on the WADA Prohibited List. Use will result in a competitive ban. DSIP is not currently prohibited but is detectable and policy may change.